Rapamycin Targets Cancer Stem Cells to Decrease Cisplatin Resistance in a Head and Neck Cancer Mouse Xenograft Model
Journal of Oral Pathology & Medicine · 2026
DOI: 10.1111/jop.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oral Pathology & Medicine, 2026. Verfasst von Khin Swe Hlaing und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Bioscience and Dental Public Health, International College of Dentistry, Walailak University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Cisplatin, Neoplastic Stem Cells, Sirolimus, Drug Resistance, Neoplasm. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cisplatin is a common chemotherapeutic agent for advanced head and neck squamous cell carcinoma (HNSCC), but treatment success is often limited by resistance. Cancer stem cells (CSCs) are known contributors to this cisplatin chemoresistance in HNSCC. The mechanistic target of rapamycin (mTOR) pathway, which is frequently dysregulated in HNSCC, plays a crucial role via the PI3K/AKT/mTOR axis in maintaining CSC populations and promoting cancer proliferation. However, the specific effects of combining rapamycin, an mTOR pathway inhibitor, with chemotherapeutic agents on CSC maintenance and overall tumorigenicity remain unclear.
Methods
We examined CSC gene expression in HNSCC cell lines (HSC4, SCC25, OT‐1109) and evaluated the therapeutic potential of combining rapamycin, an mTOR pathway inhibitor, with cisplatin on CSC using a cell viability assay. The combination was further evaluated in an HSC4 mouse xenograft model. Tumor volume and animal weight were monitored throughout treatment. Xenograft tissue analysis via immunohistochemistry assessed stem cell markers (CD133 and ALDH1A1), proliferation markers (Ki‐67), and mTOR pathway inhibition (pS6).
Results
Administration of low‐dose cisplatin enriched the CD133 + cell population but failed to decrease the tumor mass in HNSCC xenografts. In contrast, the combination of cisplatin and rapamycin significantly impeded tumor growth and minimized toxicity, concurrently reducing the population of CD133 + tumor cells.
Conclusion
These findings suggest that rapamycin enhances the mechanistic efficacy of cisplatin by specifically targeting and reducing cisplatin‐induced stemness (CD133 + CSC population). This study proposes a viable combination therapy for HNSCC involving an mTOR inhibitor and a platinum‐based drug to overcome CSC‐mediated resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Bioscience and Dental Public Health, International College of Dentistry, Walailak University, Bangkok, Thailand.
- Department of Oral Biology, Faculty of Dentistry, Mahidol University, Bangkok, Thailand.
- Translational Research in Inflammation and Immunology Research Unit, Department of Microbiology, Faculty of Medicine Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Khin Swe Hlaing, Aung Phyo Shan, Eakapong Tamboon
Zitieren
APA
Hlaing, K. S., Shan, A. P., Tamboon, E., Leelahavanichkul, A., & Amornphimoltham, P. (2026). Rapamycin Targets Cancer Stem Cells to Decrease Cisplatin Resistance in a Head and Neck Cancer Mouse Xenograft Model. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.70156
Vancouver
Hlaing KS, Shan AP, Tamboon E, Leelahavanichkul A, Amornphimoltham P. Rapamycin Targets Cancer Stem Cells to Decrease Cisplatin Resistance in a Head and Neck Cancer Mouse Xenograft Model. Journal of Oral Pathology & Medicine. 2026. doi:10.1111/jop.70156
BibTeX
@article{Hlaing2026,
author = {Hlaing, Khin Swe and Shan, Aung Phyo and Tamboon, Eakapong and Leelahavanichkul, Asada and Amornphimoltham, Panomwat},
title = {Rapamycin Targets Cancer Stem Cells to Decrease Cisplatin Resistance in a Head and Neck Cancer Mouse Xenograft Model},
journal = {Journal of Oral Pathology & Medicine},
year = {2026},
doi = {10.1111/jop.70156}
}
EUVIMED